Additional Listing

    June 14, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") hereby
    notifies the market that an application has been made to the London Stock
    Exchange and the UK Listing Authority for a total of 25,000,000 Ordinary shares
    of 5 pence each (the "Shares") to trade on the London Stock Exchange and to be
    admitted to the Official List. The Shares are to be reserved under a block
    listing relating to exchange awards made in accordance with the terms of the
    merger agreement pursuant to which the Company combined with Baxalta
    Incorporated on June 3, 2016.

    When issued, the Shares will rank equally with the existing issued Ordinary
    shares of the Company.

    Oliver Strawbridge
    Senior Assistant Company Secretary

    For further information please contact:

    Investor Relations                                                           
                                                                                 
    Sarah Elton-Farr                    seltonfarr@shire.com   +44 1256 894157   

    NOTES TO EDITORS

    Shire is the leading global biotechnology company focused on serving people
    with rare diseases and other highly specialized conditions. We have
    best-in-class products available in more than 100 countries across core
    therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal
    Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and
    Hereditary Angioedema; a growing franchise in Oncology; and an emerging,
    innovative pipeline in Ophthalmics.

    Our employees come to work every day with a shared mission: to develop and
    deliver breakthrough therapies for the hundreds of millions of people in the
    world affected by rare diseases and other high-need conditions, and who lack
    effective therapies to live their lives to the fullest.

    www.shire.com